Compare EPR Properties (EPR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Neurocrine Biosciences Inc — how do they compare? EPR Properties trades at $54.41 (market cap $4.17B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.4× EPR Properties's market cap, and EPR Properties pays a 6.84% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 45 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EPR | NBIX | |
|---|---|---|
Market Cap | $4.17B | $14.36B |
Volume | 992,716 | 1,237,180 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $185.50 |
52-Week Low | $48.71 | $123.10 |
Typical Hold Time | 45 Days | 23 Days |
Enterprise Value | $7.68B | $14.37B |
Dividend Yield | 6.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties (EPR) trades at $54.08, down 2.15% today, with a bearish technical signal and oversold RSI suggesting potential reversal. The REIT maintains strong fundamentals with 91.41% gross margins and consistent dividend payments, though recent earnings showed a Q1 miss. Analyst consensus remains positive with a $65.50 price target, representing 21% upside from current levels.
EPR offers attractive income potential with a 6.5% dividend yield and diversified real estate portfolio, but faces headwinds from rising interest rates and mixed earnings performance. The stock's current valuation at 17.44 P/E appears reasonable, though technical weakness and negative cash flow projections for 2026 warrant caution for near-term investors.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
